US 8911742
Transcutaneous immunization without heterologous adjuvant
granted A61KA61K2039/5252A61K2039/53
Quick answer
US patent 8911742 (Transcutaneous immunization without heterologous adjuvant) held by The United States of America as represented by the Secretary of the Army expires Mon Dec 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America as represented by the Secretary of the Army
- Grant date
- Tue Dec 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K2039/5252, A61K2039/53, A61K2039/54, A61K2039/545